Fewer than 50% of patients in the US receive the recommended biomarker testing to guide their treatment. Current testing options present oncologists with one of two challenges: not enough genomic information to adequately identify all treatment options, or too much complex information with an extremely slow turnaround time.
Biofidelity’s breakthrough ASPYRE technology dramatically simplifies and accelerates the detection of actionable biomarkers, enabling informed treatment decisions in a fraction of the time and at a fraction of the cost of other approaches.